BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01367535
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01367522
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01367574
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
Phase 1
Completed
- Conditions
- Healthy Males
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01367561
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01366378
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01366365
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Tolerance and Pharmacokinetics Study of MNTX Tablets
Phase 1
Completed
- Conditions
- Normal Healthy Volunteers
- Interventions
- Drug: Oral placebo
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01366339
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01366326
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
Phase 1
Completed
- Conditions
- Normal Volunteers
- Interventions
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01366352
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 546
- Registration Number
- NCT01363323
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
© Copyright 2025. All Rights Reserved by MedPath